Johnson & Johnson TAR-200 Monotherapy Shows High Complete Response in Bladder Cancer
April 28, 2025
Phase 2b SunRISe-1 study shows more than 82 percent of patients achieved complete response (CR) with more than half of responders remaining cancer-free at one year after